Understanding Heart Disease

Heart disease is not a monolith. It includes atherosclerotic disease (clogged arteries), heart failure (a weakened or stiffened heart), arrhythmias, and valvular problems. When evaluating a medication like Zepbound for heart disease, we need to specify which type we are discussing, because the evidence differs across these categories.

Two forms of heart disease are especially relevant to Zepbound. First, atherosclerotic cardiovascular disease (ASCVD), where plaque builds in the coronary and cerebral arteries and can cause heart attacks and strokes. Second, heart failure with preserved ejection fraction (HFpEF), where the heart pumps normally but is too stiff to fill properly, leading to fluid backup, exercise intolerance, and shortness of breath. types of heart disease

Obesity plays a central role in both conditions. For ASCVD, it promotes inflammation, dyslipidemia, and insulin resistance. For HFpEF, excess weight increases blood volume, raises filling pressures, and causes direct cardiac remodeling (thickening of the heart walls). The MESA study found that each 5 kg/m2 increase in BMI was associated with a 32 percent higher risk of incident heart failure.

What the Research Shows

The SUMMIT Trial: A Breakthrough for HFpEF

The SUMMIT trial, presented at the American Heart Association Scientific Sessions in November 2024, is the strongest cardiovascular evidence currently available for tirzepatide (the active ingredient in Zepbound). It enrolled 731 patients with HFpEF, a left ventricular ejection fraction of 50 percent or greater, a BMI of 30 or higher, and New York Heart Association class II-IV symptoms.

After up to 104 weeks of treatment, tirzepatide reduced the composite of cardiovascular death or worsening heart failure by 38 percent (HR 0.62, 95% CI 0.48-0.81, P less than 0.001). Worsening heart failure events alone were reduced by 46 percent.

Patients also experienced a mean weight loss of 13.9 percent, a 7.5-point improvement in KCCQ clinical summary score (a validated measure of heart failure symptoms and quality of life), and significant improvements in 6-minute walk distance. CRP, a marker of systemic inflammation, decreased by 36 percent.

Why SUMMIT Matters for HFpEF

HFpEF has been one of the most frustrating conditions in cardiology. Unlike heart failure with reduced ejection fraction (HFrEF), which responds to multiple drug classes (ACE inhibitors, beta-blockers, mineralocorticoid antagonists, SGLT2 inhibitors), HFpEF has historically had very few proven treatments. The SGLT2 inhibitor empagliflozin showed modest benefit in the EMPEROR-Preserved trial (21 percent reduction in HF hospitalization), but tirzepatide's 38 percent composite reduction in SUMMIT represents a substantially larger effect.

SURMOUNT-MMO: The Atherosclerotic Outcomes Trial

For the question of whether Zepbound prevents heart attacks and strokes, we must await SURMOUNT-MMO. This trial is enrolling approximately 15,000 adults with established ASCVD or multiple cardiovascular risk factors and obesity but without diabetes. The primary endpoint is three-point MACE (cardiovascular death, nonfatal MI, nonfatal stroke). Recruitment began in 2023, and results are expected around 2027.

Metabolic Risk Factor Improvements

While awaiting SURMOUNT-MMO, the SURMOUNT weight management trials provide indirect evidence of cardiovascular benefit through comprehensive risk factor improvement. At the 15 mg dose: weight decreased by 22.5 percent, systolic BP decreased by 7.2 mmHg, triglycerides decreased by 27 percent, CRP decreased by approximately 37 percent, and HOMA-IR improved by 60 percent.

How Zepbound May Help

Zepbound's dual GLP-1/GIP mechanism may provide cardiovascular benefits through pathways that overlap with, but are not identical to, those of single-receptor GLP-1 agonists. Zepbound mechanism of action

Superior weight loss and hemodynamic relief: The 20 to 22.5 percent weight loss produced by Zepbound exceeds what any single-receptor GLP-1 agonist achieves. Greater weight loss means greater reductions in blood volume, cardiac preload, and afterload, all of which directly reduce the strain on the heart. For HFpEF patients, this translates to lower filling pressures and improved cardiac output.

GIP receptor signaling in the heart: While research is still early, preclinical studies suggest that GIP receptors are expressed in cardiac tissue and that GIP signaling may have direct cardioprotective effects. Ussher et al. demonstrated in Circulation Research that GIP receptor activation reduced infarct size in animal models of myocardial ischemia.

Epicardial and pericardial fat reduction: These fat depots directly surround the heart and are highly inflammatory. Weight loss with incretin-based therapies substantially reduces epicardial fat volume, which may improve cardiac mechanics and reduce the inflammatory signals that promote atrial fibrillation and heart failure progression.

Comprehensive metabolic correction: By simultaneously improving blood pressure, lipids, insulin sensitivity, and inflammation, Zepbound creates a metabolic environment that is less conducive to atherosclerosis progression and cardiac remodeling.

Important Safety Information

Zepbound is currently FDA-approved for chronic weight management only. It does not yet have a cardiovascular indication. Any use for heart disease would be considered off-label until regulatory authorities review the SUMMIT and/or SURMOUNT-MMO data for a potential indication.

For heart disease patients, specific safety considerations include: risk of dehydration from GI side effects in patients taking diuretics, the need for careful monitoring of kidney function and electrolytes, and awareness of the slight increase in heart rate (2 to 4 bpm) in patients with arrhythmias or conduction abnormalities.

Zepbound carries a boxed warning about thyroid C-cell tumors in rodent studies and is contraindicated in patients with medullary thyroid carcinoma or MEN2. Gallbladder events and rare pancreatitis cases have been reported.

Patients with heart failure should be managed by a cardiologist who can adjust diuretics and other heart failure medications as weight decreases and hemodynamics improve. managing heart failure medications during weight loss

Who Might Benefit

Based on available evidence, Zepbound may be most relevant for heart disease in these populations:

• Patients with HFpEF and obesity (BMI 30 or higher), where the SUMMIT data provide direct evidence of benefit
• Adults with obesity and multiple cardiovascular risk factors who need comprehensive metabolic improvement while awaiting formal ASCVD outcomes data
• People with type 2 diabetes and cardiovascular risk who might benefit from tirzepatide's dual mechanism (prescribed as Mounjaro in this context)

For patients with established ASCVD and no diabetes who want proven cardiovascular event reduction today, semaglutide (Wegovy) has completed cardiovascular outcomes data from SELECT. Zepbound may become an equivalent or superior option once SURMOUNT-MMO reports, but the data are not yet available.

How to Talk to Your Doctor

The conversation about Zepbound and heart disease will depend on your specific cardiac condition:

• If you have HFpEF and obesity: Reference the SUMMIT trial specifically. Ask whether tirzepatide could complement your current heart failure regimen (diuretics, SGLT2 inhibitors, etc.)
• If you have ASCVD: Acknowledge that SURMOUNT-MMO is still ongoing. Ask whether Zepbound for weight management is reasonable while awaiting the cardiovascular data, or whether Wegovy with its proven ASCVD outcomes is preferable
• For any cardiac condition: Emphasize the need for coordinated care between your cardiologist and the prescribing provider, particularly around diuretic dosing and fluid balance

talking to your cardiologist about GLP-1 therapy

Frequently Asked Questions

Is Zepbound approved for heart disease?

No. As of early 2026, Zepbound is FDA-approved only for chronic weight management. The SUMMIT heart failure data may support a future regulatory filing for HFpEF, and SURMOUNT-MMO may support an ASCVD indication, but neither has been submitted or approved yet.

Is Zepbound or Wegovy better for heart disease?

For ASCVD (heart attacks and strokes), Wegovy has completed outcomes data (SELECT) showing a 20 percent event reduction. Zepbound's ASCVD outcomes trial is still running. For HFpEF, tirzepatide (SUMMIT) has shown a larger treatment effect than semaglutide (STEP-HFpEF), though cross-trial comparisons should be interpreted cautiously.

Can Zepbound improve heart failure symptoms?

Yes. In the SUMMIT trial, tirzepatide significantly improved heart failure symptoms as measured by the Kansas City Cardiomyopathy Questionnaire, improved exercise capacity (6-minute walk distance), and reduced heart failure hospitalizations and urgent visits.

Taking the Next Step

The evidence for Zepbound in heart disease is building rapidly. The SUMMIT trial has already established it as a potentially transformative therapy for HFpEF, and SURMOUNT-MMO may do the same for atherosclerotic disease. For patients at the intersection of obesity and heart disease, this is a space worth watching closely.

At FormBlends, we help you keep pace with the fastest-moving area of metabolic cardiology. Explore our resources and discuss your options with your healthcare team. GLP-1 medications overview